EXT-608 is under clinical development by Extend Biosciences and currently in Phase I for Hypoparathyroidism. According to GlobalData, Phase I drugs for Hypoparathyroidism have a 70% phase transition ...
U.S. FDA Orphan Drug exclusivity provides seven years of market exclusivity for YORVIPATH in the United States for the treatment of hypoparathyroidism in adults COPENHAGEN, Denmark, Sept. 11, 2024 ...
After thyroid surgery, the PTH test may also be used to make sure the parathyroid glands are working well after being manipulated or re-implanted. Hypoparathyroidism and Hyperparathyroidism ...